Milyon USD cinsinden finanslar. Mali yıl Şubat - Ocak'tır.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Hasılat
20,054
18,675
17,034
15,268
10,290
5,612
Hasılat Artışı (YoY)
17%
10%
12%
48%
83%
41%
Satınalma Maliyeti
11,500
11,024
10,206
8,544
5,461
3,079
Brüt Kâr
8,553
7,650
6,827
6,724
4,828
2,532
Satış, Genel ve İdari
2,297
2,298
2,109
1,691
1,157
726
Araştırma ve Geliştirme
765
766
785
682
501
303
İşletme Giderleri
2,983
2,821
2,680
2,166
1,520
888
Diğer Finansman Gelirleri (Giderleri)
-5
-10
-10
-10
-9
--
Kâr Öncesi Gelir
6,154
4,834
4,173
5,357
3,993
1,965
Kira Vergisi Gideri
1,232
889
603
807
484
273
Net Kâr
4,196
3,356
3,399
4,420
3,388
1,688
Net Income Growth
Kâr Artışı
59%
-1%
-23%
30%
101%
67%
Dolaşım Daki Hisse Senetleri (Dilüte Edilmiş)
4,185.75
4,227.16
4,348.87
4,375.9
4,421.79
4,209.16
Hisse Değişimi (Yıllık Üst Üste)
-2%
-3%
-1%
-1%
5%
5%
EPS (Diluted)
0.98
0.78
0.78
1.01
0.76
0.4
EPS Artışı
62%
0%
-23%
32%
91%
57.99%
Öz sermaye akışı
1,759
1,287
447
-326
-3,091
-4,143
Hisse Başı Öz Kaynak Akışı
--
--
--
--
--
--
Brüt Karşılık
42.64%
40.96%
40.07%
44.03%
46.91%
45.11%
Faaliyet Kâr Marjı
27.77%
25.85%
24.34%
29.84%
32.14%
29.29%
Kâr Marjı
20.92%
17.97%
19.95%
28.94%
32.92%
30.07%
Özsermaye Karlılık Oranı
8.77%
6.89%
2.62%
-2.13%
-30.03%
-73.82%
EBITDA
--
6,266
5,316
5,357
3,789
1,947
EBITDA Marjinali
--
33.55%
31.2%
35.08%
36.82%
34.69%
D&A EBITDA için
--
1,437
1,169
800
481
303
Faaliyet Kârı
5,570
4,829
4,147
4,557
3,308
1,644
Faaliyet Kâr Marjı
27.77%
25.85%
24.34%
29.84%
32.14%
29.29%
Verilen Vergi Oranı
20.01%
18.39%
14.45%
15.06%
12.12%
13.89%
Önemli İstatistikler
Önceki Kapanış
$4.3
Açılış fiyatı
$5.26
Günün Aralığı
$5.25 - $5.26
52 haftalık aralık
$2.25 - $5.6
İşlem hacmi
32.2K
Ort.Hacim
7.1K
EPS (TTM)
0.14
Dividend yield
--
Piyasa Değeri
$21.6B
Wuxi Biologics (Cayman) Inc nedir?
Wuxi Biologics (Cayman), Inc. is an investment holding company, which provides end-to-end solutions and services for biologics discovery, development, and manufacturing services and manufacturing of biologics products. The company is headquartered in Wuxi, Jiangsu and currently employs 12,552 full-time employees. The company went IPO on 2017-06-13. The firm mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The firm mainly conducts its business in the domestic and overseas markets.